Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharnyx

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2291-2296

  Alkotyfan, Khaled ^a   Wiegand, Susanne ^a   Müller, Hans Helge ^b   Windfuhr, Jochen P ^c   Werner, Jochen A ^a   Sesterhenn, Andreas M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Krankenhaus Maria Hilf Daun   (Germany)

Author keywords

Cyfra 21 1; Follow up; Oropharyngeal cancer; Squamous cell carcinoma; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 19 FRAGMENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISTANT METASTASIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; NECK DISSECTION; OROPHARYNX CARCINOMA; PARAMETER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATIN-19; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955060122     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Sawant SS, Zingde SM and Vaidya MM: Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol 44: 722-732, 2008.
2. Fohr JK and Lee JH: Identical but different: Mechanism of cancer development and response to treatment for human papilloma virus-related and non-related squamous cell cancer of the head and neck. S D Med 61(12): 453-455, 2008.
3. Marur S and Forastiere AA: Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83: 489-501, 2008.
4. Ho HC, Lee MS, Hsiao SH, Hwang JH, Hung SK, Chou P and Lee CC: Squamous cell carcinoma of the oral cavity in young patients: a matched-pair analysis. Eur Arch Otorhinolaryngol 265(1): 57-61, 2008.
5. Chung CH and Gillison ML: Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15(22): 6758-6762, 2009.
6. Tachezy R, Klozar J, Rubenstein L, Smith E, Saláková M, Smahelová J, Ludvíková V, Rotnáglová E, Kodet R and Hamsíková E: Demographic and risk factors in patients with head and neck tumors. J Med Virol 81: 878-887, 2009.
7. Sesterhenn AM, Muller HH, Wiegand S, Teymoortash A, Folz BJ and Werner JA: Cancer of the oro- and hypopharynx - when to expect recurrences? Acta Otolaryngol 128: 925-929, 2008.
8. Lim YC, Hong HJ, Baek SJ, Park JH, Kim GE, Lee CG, Lew DH, Lee WJ and Choi EC: Combined surgery and postoperative radiotherapy for oropharyngeal squamous cell carcinoma in Korea analysis of 110 cases. Int J Oral Maxillofac Surg 37(12): 1099-1105, 2008.
9. Al-Shagahin H, Alkotyfan K, Müller HH, Sesterhenn AM and Werner JA: Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res 29: 3421-3425, 2009.
10. Banal A, Hacene K, Berthelot-Ruff E, Mahé E, Fontana X and Pichon MF: Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour Biol 22: 27-35, 2001.
11. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M and Gruener N: Cyfra 21-1 a new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121: 177-181, 1995.
12. Kuropkat C and Werner JA: Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117: 1007-1008, 2003.
13. Niemann AM: Cytokeratin 19 und dessen serumlösliche Fragmente: Untersuchungen zur Anwendbarkeit von CYFRA 21-1 bei Patienten mit Plattenepithelkarzinomen der oberen Luft- und Speisewege. Kiel, Univ., Dissertation, 1996.
14. Niemann AM, Goeroegh T, Gottschlich S, Lippert BM and Werner JA: Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 17: 2859-2860, 1997.
15. Zhong LP, Zhu HG, Zhang CP, Chen WT and Zhang ZY: Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg 36: 230-234, 2007.
16. Boucek J, Mrkvan T, Chovanec M, Kuchar M, Betka J, Boucek V, Hladikova M, Betka J, Eckschlager T and Rihova B: Regulatory T-cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med, 2009.
17. Kuropkat C, Lippert BM and Werner JA: Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Oncology 63: 280-285, 2002. (Pubitemid 36151323)
18. Stieber P, Bodenmüller H, Banauch D, Hasholzner U, Dessauer A, Ofenloch-Hähnle B, Jaworek D and Fateh-Moghadam A: Cytokeratin 19 fragments: a new marker for non-small cell lung cancer. Clin Biochem 26: 301-304, 1993.
19. Céruse P, Rabilloud M, Charrié A, Dubreuil C and Disant F: Study of CYFRA 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 114: 768-776, 2005. (Pubitemid 41502379)
20. Doweck I, Barak M, Uri N and Greenberg E: The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83: 1696-1701, 2000.
21. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 6 edition Wiley-Liss; pp. 31-50, 2002.
22. Hoffmann-Fazel A, Hoffmann M, Gottschlich S, Maass JD, Rudert H and Maune S: Cyfra 21-1 in diagnosis of distant metastasis of head and neck carcinoma. Anticancer Res 23: 917-920, 2003. (Pubitemid 36750895)
23. Haigentz M Jr, Silver CE, Corry J, Genden EM, Takes RP, Rinaldo A and Ferlito A: Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 266(12): 1845-1855, 2009.
24. Lin DT, Cohen SM, Coppit GL and Burkey BB: Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngol Clin North Am 38: 59-74, 2005.
25. Deng YF, Chen P, Lin YZ, Le JZ, Wu XL, Yu MQ, Zhuang PY and Gao MH: Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117: 190-1904, 2003.
26. Maass JD, Hoffmann-Fazel A, Goeroegh T, Hoffmann M, Meyer JE, Gottschlich S, Rudert H and Maune S: Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res 20: 2241-2243, 2000.
27. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P and Fateh-Moghadam A: CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 16: 3117-3124, 1996. (Pubitemid 26390259)
28. Büntzel J, Hornig A, Glatzel M, Micke O, Bruns F, Schäfer U and Fröhlich D: Tumor markers and lymphatic metastasis in head and neck cancer patients. Anticancer Res 25: 1539-1542, 2005. (Pubitemid 40896760)